Renal CancerNCT02087852
Kidney Cancer DNA Registry
An observational study of Renal Cancer, run by Memorial Sloan Kettering Cancer Center at 7 sites in United States.
Trial summary
This registry will help us develop better methods of: Preventing these cancers Diagnosing these cancers Treating these cancers Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Renal Cancer
- What is being tested?
- salvia for germline DNA, the Kidney Cancer Questionnaire and Family History Questionnaire (when applicable)
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 750 participants
- Where
- 7 sitesUnited States
- Study dates
- Mar 2014to Mar 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Urologists, clinical geneticists, and medical oncologists at MSKCC, along with study personnel will identify patients, family members, and unaffected controls that may be eligible for the registry. Patients and families may also be directly referred to the MSKCC study team by any MSKCC physician, external physician, or by the family itself.
Who may be able to join
- Kidney Cancer Case Cohort:
- Must be ≥ 18 years of age AND
- Must be an English-speaker AND
- Must have a diagnosis or suspicion of kidney cancer
- Family Member Cohort:
- Must be ≥ 18 years of age AND
Show all 13Show fewer
- Must be an English-speaker AND
- Must be a blood relative of the proband. Family members of probands including mother, father, sisters, brothers, half-sisters, half-brothers, daughters, sons, grandmothers, grandfathers, as well as aunts and uncles are eligible. These individuals need not have kidney cancer, as they will be used for segregation analysis of suspected variants found in the proband; requesting DNA from relatives is required.
- Control Cohort:
- Must be ≥ 18 years of age AND
- Must be an English-speaker AND
- Must not have a personal history of cancer, with the exception of nonmelanoma skin cancer, AND
- Must not be a blood relative of any cases or controls enrolled in this study
Who cannot join
- Patients who, in the opinion of the primary MSKCC clinician or the investigator, have a condition that precludes their ability to provide an informed consent
Trial locations and contacts
7 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Jonathan Coleman, MD contact
Kenneth Offit, MD contact
7 sites in 1 country
United States7 sites, 7 recruiting
- Recruiting
Memorial Sloan Kettering at Basking Ridge (Consent and Follow-up)
Basking Ridge, New Jersey, 07920
Jonathan Coleman, MD, 646-422-4432
- Recruiting
Memorial Sloan Kettering Commack (Consent and Follow-up)
Commack, New York, 11725
Jonathan Coleman, MD, 646-422-4432
- Recruiting
Memorial Sloan Kettering Westchester (Consent and Follow up)
Harrison, New York, 10604
Jonathan Coleman, MD, 646-422-4432
- Recruiting
Memorial Sloan Kettering Monmouth (Consent and Follow up)
Middletown, New Jersey, 07748
Jonathan Coleman, MD, 646-422-4432
- Recruiting
Memorial Sloan Kettering Bergen (Consent and Follow up )
Montvale, New Jersey, 07645
Jonathan Coleman, MD, 646-422-4432
- Recruiting
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065
Jonathan Coleman, MD, 646-422-4432
Kenneth Offit, MD, 646-888-4050
- Recruiting
Memorial Sloan Kettering Nassau (Consent and Follow-Up)
Uniondale, New York, 11553
Jonathan Coleman, MD, 646-422-4432
About this study
This registry will help us develop better methods of:
- Preventing these cancers
- Diagnosing these cancers
- Treating these cancers
- Conditions
- Renal Cancer
- Being tested
- salvia for germline DNA, the Kidney Cancer Questionnaire, Family History Questionnaire (when applicable), Blood draw, Epidemiologic Questionnaire
- Keywords
- Questionnaire, DNA, saliva, kidney cancer, 13-218, high risk
- Medical subject headings
- Kidney Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
salvia for germline DNAOther
the Kidney Cancer QuestionnaireBehavioural
Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
Family History Questionnaire (when applicable)Behavioural
Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
Blood drawOther
Epidemiologic QuestionnaireBehavioural
Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires.
| Study group | Role | What they receive |
|---|---|---|
| kidney cancer patients receiving care at MSKCC | Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire and complete the Epidemiologic Questionnaire (when applicable,), and providing a blood sample and saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity. Receives: Other: salvia for germline DNA; Behavioral: the Kidney Cancer Questionnaire; Behavioral: Family History Questionnaire (when applicable); Other: Blood draw; Behavioral: Epidemiologic Questionnaire | |
| relatives of patients with kidney cancer | Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire (when applicable,), and providing a saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity. Receives: Other: salvia for germline DNA; Behavioral: the Kidney Cancer Questionnaire; Behavioral: Family History Questionnaire (when applicable) | |
| healthy controls who are unrelated & do not have hx of cancer | Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire (when applicable,), and providing a saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity. Receives: Other: salvia for germline DNA; Behavioral: the Kidney Cancer Questionnaire; Behavioral: Family History Questionnaire (when applicable) | |
| high risk | Participation will consist of completing the Epidemiologic Questionnaire, Family History Questionnaire (if + FH), provide saliva and blood sample , referral for screening evaluation Receives: Other: salvia for germline DNA; Behavioral: Family History Questionnaire (when applicable); Other: Blood draw; Behavioral: Epidemiologic Questionnaire |
What is being measured
The primary outcome is the main question the study is designed to answer.
establish a kidney cancer registry
with detailed epidemiologic data and germline DNA available for next generation sequencing from consenting patients, selected family members, and healthy unrelated controls.
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Mar 2014 (estimated)
- Study startMar 2014
- Primary completionMar 2027 (estimated)
- Study completionMar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Renal CancerStudies of the same condition, open and under way.
- More trials run by Memorial Sloan Kettering Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 750 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jonathan Jonathan, MD, Principal investigator, Memorial Sloan Kettering Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02087852
- Sponsor's protocol ID
- 13-218
- Status last verified
- Apr 2026
- First submitted
- 12 Mar 2014
- Last updated
- 9 Apr 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Kidney Cancer DNA Registry
- ClinicalTrials.gov ID
- NCT02087852
- Acronym / sponsor ID
- 13-218
- Conditions
- Renal Cancer
- Keywords
- Questionnaire, DNA, saliva, kidney cancer, 13-218, high risk
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 750 participants (estimated)
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterUniversity, hospital or other
- Study start
- Mar 2014
- Primary completion
- Mar 2027 (estimated)
- Study completion
- Mar 2027 (estimated)
- First posted
- 14 Mar 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This registry will help us develop better methods of:
- Preventing these cancers
- Diagnosing these cancers
- Treating these cancers
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| kidney cancer patients receiving care at MSKCC | – | Other: salvia for germline DNA, Behavioral: the Kidney Cancer Questionnaire, Behavioral: Family History Questionnaire (when applicable), Other: Blood draw, Behavioral: Epidemiologic QuestionnaireParticipation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire and complete the Epidemiologic Questionnaire (when applicable,), and providing a blood sample and saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity. |
| relatives of patients with kidney cancer | – | Other: salvia for germline DNA, Behavioral: the Kidney Cancer Questionnaire, Behavioral: Family History Questionnaire (when applicable)Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire (when applicable,), and providing a saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity. |
| healthy controls who are unrelated & do not have hx of cancer | – | Other: salvia for germline DNA, Behavioral: the Kidney Cancer Questionnaire, Behavioral: Family History Questionnaire (when applicable)Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire (when applicable,), and providing a saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity. |
| high risk | – | Other: salvia for germline DNA, Behavioral: Family History Questionnaire (when applicable), Other: Blood draw, Behavioral: Epidemiologic QuestionnaireParticipation will consist of completing the Epidemiologic Questionnaire, Family History Questionnaire (if + FH), provide saliva and blood sample , referral for screening evaluation |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Urologists, clinical geneticists, and medical oncologists at MSKCC, along with study personnel will identify patients, family members, and unaffected controls that may be eligible for the registry. Patients and families may also be directly referred to the MSKCC study team by any MSKCC physician, external physician, or by the family itself.
Key inclusion criteria (13 listed)
- Must be ≥ 18 years of age AND
- Must be an English-speaker AND
- Must have a diagnosis or suspicion of kidney cancer
- Must be ≥ 18 years of age AND
- Must be an English-speaker AND
Key exclusion criteria (1 listed)
- Patients who, in the opinion of the primary MSKCC clinician or the investigator, have a condition that precludes their ability to provide an informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| salvia for germline DNA | Other | healthy controls who are unrelated & do not have hx of cancer, high risk, kidney cancer patients receiving care at MSKCC, relatives of patients with kidney cancer |
| the Kidney Cancer QuestionnairePatients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires. | Behavioural | healthy controls who are unrelated & do not have hx of cancer, kidney cancer patients receiving care at MSKCC, relatives of patients with kidney cancer |
| Family History Questionnaire (when applicable)Patients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires. | Behavioural | healthy controls who are unrelated & do not have hx of cancer, high risk, kidney cancer patients receiving care at MSKCC, relatives of patients with kidney cancer |
| Blood draw | Other | high risk, kidney cancer patients receiving care at MSKCC |
| Epidemiologic QuestionnairePatients will complete the appropriate surveys on either paper or on the computer/iPad in the office using REDCap software. If patients are unable to complete their questionnaires at the time of their in-office visit, a link to the questionnaires in REDCap will be emailed to them. The survey data that is collected in REDCap will be stored in REDCap. Clinic staff may also call patients to remind patients to complete questionnaires. | Behavioural | high risk, kidney cancer patients receiving care at MSKCC |
Primary outcome
establish a kidney cancer registry
Time frame: 5 years
with detailed epidemiologic data and germline DNA available for next generation sequencing from consenting patients, selected family members, and healthy unrelated controls.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Apr 2026.
- Memorial Sloan Kettering Cancer CenterLink provided by the sponsor.
Related trials for Renal Cancer
Not yet recruitingObservational study
Assessment of Intelligent Algorithms for Detection, Diagnosis and Risk Stratification of Tumors of the Kidney and Prostate
Kidney Cancers, Prostate Cancer
Active, not recruitingPhase 3
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Active, not recruitingPhase 1/2
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence
RecruitingPhase 2/3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
RecruitingPhase 2
Prospective Study of Cadonilimab With Lenvatinib in Renal Cell Carcinoma
Renal Cell Carcinoma (Kidney Cancer), Clear Cell Renal Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jonathan Coleman, MD contact
Kenneth Offit, MD contact
Jonathan Jonathan, MD principal investigator
Memorial Sloan Kettering Cancer Center
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Renal Cancer, run by Memorial Sloan Kettering Cancer Center at 7 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jonathan Coleman, MD (646-422-4432), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
establish a kidney cancer registry (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Apr 2026.